0000950170-24-015465.txt : 20240214 0000950170-24-015465.hdr.sgml : 20240214 20240214185643 ACCESSION NUMBER: 0000950170-24-015465 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240212 FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SEIDENBERG BETH C CENTRAL INDEX KEY: 0001184592 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41947 FILM NUMBER: 24641369 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kyverna Therapeutics, Inc. CENTRAL INDEX KEY: 0001994702 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831365441 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5980 HORTON STREET STREET 2: SUITE 550 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 5106268331 MAIL ADDRESS: STREET 1: 5980 HORTON STREET STREET 2: SUITE 550 CITY: EMERYVILLE STATE: CA ZIP: 94608 4 1 ownership.xml 4 X0508 4 2024-02-12 0001994702 Kyverna Therapeutics, Inc. KYTX 0001184592 SEIDENBERG BETH C C/O KYVERNA THERAPEUTICS, INC. 5980 HORTON ST., STE 550 EMERYVILLE CA 94608 true false true false false Common Stock 2024-02-12 4 C false 3787940 A 3787940 I See Footnote Common Stock 2024-02-12 4 C false 735984 A 735984 I See Footnote Series A-1 Redeemable Convertible Preferred Stock 2024-02-12 4 C false 4401771 0 D Common Stock 967188 0 I See Footnote Series A-2 Redeemable Convertible Preferred Stock 2024-02-12 4 C false 8830901 0 D Common Stock 1940388 0 I See Footnote Series B Redeemable Convertible Preferred Stock 2024-02-12 4 C false 4006624 0 D Common Stock 880364 0 I See Footnote Series B Redeemable Convertible Preferred Stock 2024-02-12 4 C false 3349538 0 D Common Stock 735984 0 I See Footnote Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any. Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any. The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. By: /s/ Ryan Jones, as Attorney-in-Fact 2024-02-14